<unk>  (rINN) is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, South Africa, and Brazil, under the trade name Prexige (sometimes misquoted as "Prestige" by the media). The TARGET study (Therapeutic Arthritis Research and Gastrointestinal Event Trial) was conducted with more than 18,000 patients to test its gastrointestinal and cardiovascular safety against Naproxen and Ibuprofen and also study its efficacy against these two NSAIDs.
In November 2006, Prexige received marketing approval for all European Union countries through a common procedure called MRP. As of 2007, the Food and Drug Administration (FDA) has not yet granted approval for its sale in the United States.<unk>  has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.
The FDA rejected Prexige as a trade name for<unk>  in 2003.  The FDA Division of Medication Errors and Technical Support (DMETS) subsequently recommended against the alternative name Prexede. The planned trade name for<unk>  in the US has not been disclosed to the public.
On September 27, 2007, the US Food and Drug Administration issued a not approvable letter for<unk> , requiring additional safety data.
Lumiracoxib
Firocoxib
Valdecoxib
Robenacoxib
Rofecoxib
Mavacoxib
Cimicoxib
Celecoxib